Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1990 Feb;42(2):175-8.
doi: 10.4269/ajtmh.1990.42.175.

Equine Rabies Immune Globulin: A Product With an Undeserved Poor Reputation

Affiliations

Equine Rabies Immune Globulin: A Product With an Undeserved Poor Reputation

H Wilde et al. Am J Trop Med Hyg. .

Abstract

Four hundred nineteen patients exposed to rabies in Thailand were treated with equine rabies immune globulin (ERIG) manufactured by Sclavo of Italy, a product also licensed in the United States of America. They were followed for a minimum of 1 month after ERIG injection and rabies vaccine administration. Adverse serum sickness-like reactions were noted in 15 patients (3.58%). These were clinically acceptable and only 1 of these patients required corticosteroid therapy and short term hospitalization for serum sickness. ERIG is approximately 1/10 of the cost of human rabies immune globulin (HRIG), which is not generally available in developing countries. ERIG is a safe and underutilized essential biological when HRIG is not affordable or available.

Similar articles

See all similar articles

Cited by 5 articles

Publication types

LinkOut - more resources

Feedback